News and Trends 7 Jun 2022
Yumanity selling neurology assets and merging with Kineta
U.S. biopharma company Yumanity Therapeutics, Inc. is selling off its lead clinical-stage neurodegenerative product candidate YTX-7739 to Janssen Pharmaceutica NV,…